STOCK TITAN

Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in Cowen’s 42nd Annual Health Care Conference, scheduled from March 7th to March 9th, 2022. The company will be featured in a panel addressing leukemias and myeloproliferative neoplasms on March 7th at 10:30 a.m. ET. Foghorn is engaged in developing innovative medicines that target genetic dependencies in the chromatin regulatory system, having multiple oncology product candidates, with two in clinical studies. A webcast of the panel will be available for 90 days post-event on their website.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate on a panel at Cowen’s 42nd Annual Health Care Conference which is being held virtually March 7th through March 9th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Panel Details

Title: Leukemias/Myeloproliferative Neoplasms (MPN) Panel

Panel date and time: Monday, March 7th, 10:30 a.m. ET

Please find a link to the panel here.

A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com and will be available for 90 days.

About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Gregory Kelley, Ogilvy (Media)
gregory.kelley@ogilvy.com

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com

 


FAQ

When is Foghorn Therapeutics participating in the Cowen Health Care Conference?

Foghorn Therapeutics will participate in the Cowen’s 42nd Annual Health Care Conference from March 7th to March 9th, 2022.

What is the focus of Foghorn Therapeutics at the Cowen Conference?

Foghorn Therapeutics will focus on a panel about leukemias and myeloproliferative neoplasms on March 7th at 10:30 a.m. ET.

How can I access the Foghorn Therapeutics panel webcast?

The webcast of the Foghorn Therapeutics panel will be available under 'Events & Presentations' on their website for 90 days after the event.

What is the significance of Foghorn's Gene Traffic Control platform?

Foghorn's Gene Traffic Control platform focuses on identifying and validating drug targets within the chromatin regulatory system, aiming to innovate treatments for various diseases.

What is the stock symbol for Foghorn Therapeutics?

The stock symbol for Foghorn Therapeutics is FHTX.

Foghorn Therapeutics Inc.

NASDAQ:FHTX

FHTX Rankings

FHTX Latest News

FHTX Stock Data

258.51M
44.98M
18.98%
72.09%
1.71%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE